TBG Inhibitors

Chemical inhibitors of Thyroxine-binding globulin (TBG) can impede the protein's function through various mechanisms, primarily focusing on the disruption of its thyroxine-binding capacity. Iodoacetamide and N-Ethylmaleimide can inhibit TBG by targeting cysteine residues within the protein. These agents alkylate the thiol groups of cysteines, which are essential for the maintenance of TBG's structure and function, particularly its ability to bind to thyroxine. Similarly, auranofin, a gold-containing compound, and p-Chloromercuribenzoate, a mercurial compound, can bind to TBG's cysteine residues, leading to a loss of function. This binding can prevent TBG from properly binding to thyroxine, thus inhibiting its physiological role in thyroid hormone transport.

Other chemicals act as inhibitors by potentially disrupting TBG's metal ion dependencies or by mimicking its natural ligands. Ellagic acid, for instance, chelates with metal ions that might be key for TBG's structure and functionality, while Methotrexate competes with thyroxine at TBG's binding site due to its structural similarity, which can inhibit the protein's ability to bind its natural ligand. Metallic compounds such as Tetrachloroplatinate(II), Cadmium chloride, and Lead(II) acetate can also inhibit TBG by replacing or binding to metal co-factors essential for its activity, or by disrupting crucial disulfide bonds. Mercuric chloride and Phenylarsine oxide further inhibit TBG by binding irreversibly to thiol groups or vicinal thiol groups, respectively, affecting TBG's conformation and its capacity to bind thyroxine. Lastly, clioquinol acts as a metal chelator, potentially sequestering metal ions and thereby disrupting the metalloprotein nature of TBG, leading to inhibition of its thyroxine-binding ability. Each of these chemicals targets TBG's ability to interact with thyroxine, ensuring the inhibition of its primary biological function without affecting gene expression or protein modulation.